IP Verse

Treatment Of Hand Eczema - EP3405197

The patent EP3405197 was granted to LEO Pharma on Sep 6, 2023. The application was originally filed on Jan 20, 2017 under application number EP17701828A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3405197

LEO PHARMA
Application Number
EP17701828A
Filing Date
Jan 20, 2017
Status
Granted And Under Opposition
Aug 4, 2023
Grant Date
Sep 6, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

VENNER SHIPLEYJun 6, 2024RUSSELLADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTEP2813228
INTERNATIONAL-SEARCH-REPORTUS2013302298
OPPOSITIONEP2460806
OPPOSITIONEP2813228
OPPOSITIONUS2013302298

Non-Patent Literature (NPL) Citations (4) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "A Study to Evaluate the Safety and E!cacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis", ClinicalTrials.gov ID NCT03011892, (20170105), ClinicalTrials.gov ID NCT03011892, URL: https://clinicaltrials.gov/study/NCT03011892?term=NCT03011892&rank=1&tab=history&a=2, XP093192196-
OPPOSITION- Tanimoto Atsuo; Ogawa Yoshihiro; Oki Chika; Kimoto Yukari; Nozawa Keisuke; Amano Wataru; Noji Satoru; Shiozaki Makoto; Matsuo Akira; Shinozaki Yuichi; Matsushita Mutsuyoshi, "Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo", Inflammation Research, Birkhaeuser verslag , Basel, CH, CH , (20141112), vol. 64, no. 1, doi:10.1007/s00011-014-0782-9, ISSN 1023-3830, pages 41 - 51, XP035421081
OPPOSITION- R. Bissonnette; K.A. Papp; Y. Poulin; M. Gooderham; M. Raman; L. Mallbris; C. Wang; V. Purohit; C. Mamolo; J. Papacharalambous; W.C. Ports, "Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial", British journal of dermatology (1951), Wiley, (20160924), vol. 175, no. 5, doi:10.1111/bjd.14871, ISSN 0007-0963, pages 902 - 911, XP071033521
OPPOSITION- Ostojic Alen; Vrhovac Radovan; Verstovsek Srdan, "Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB, GB , (20110101), vol. 7, no. 9, doi:10.2217/fon.11.81, ISSN 1479-6694, pages 1035 - 1043, XP008150477

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents